Biomea and A2A form
Biomea Fusion to develop
reversible MENIN Program
Biomea Fusion
We are a biopharmaceutical company focused on the discovery, development and commercialization of irreversible small molecules to treat patients with genetically defined cancers. An irreversible small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional reversible drugs including greater target selectivity, lower drug exposure and the ability to drive a deeper, more durable response.
Leveraging our extensive expertise in irreversible binding chemistry and development, we built our proprietary FUSION™ System platform to advance a pipeline of novel irreversible therapies. Our lead product candidate, BMF-219, is an orally bioavailable, potent and selective irreversible inhibitor of MENIN, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. Beyond BMF-219, we are utilizing our novel platform to develop irreversible treatments against other high-value oncogenic drivers of cancer. Our goal is to utilize our capabilities and platform to become a leader in developing irreversible small molecules in order to maximize the depth and durability of clinical benefit when treating various cancers.
The name biomea derives from the Greek word bios, meaning “life,” and the Latin word mea, meaning “my.”
At Biomea Fusion, we develop medicines to improve the life of the individual.
“At Biomea, we utilize our FUSION™ System to design and develop irreversible binding therapies to effectively stop tumor proliferation with minimal side effects. We want to create patient-friendly medicines that harmonize with the individual.”
Thomas Butler
CEO of Biomea Fusion
History
2017
2nd and 3rd Generation
reversible molecules
designed2018
2018
Biomea Fusion becomes a JLABS,
South San Francisco resident
Biomea Fusion builds out its
proprietary irreversible
binding technologyLead candidates
selected for MENIN
MLL-Fusion and MENIN
dependent cancers2019
2020
Biomea Fusion receives Series A
Syndicate financing of
$56,000,000 to support the
development of its portfolio of
irreversible inhibitors
“Ultimately, we strive to achieve cures for patients, bringing them back to normal, to how life used to be. This is what keeps us going day in and day out.”
Ramses Erdtmann
President of Biomea Fusion
Biomea Fusion, Inc. was formed in 2017 by a small group of biotech executives. We came together after a career in drug design and development with the common goal of achieving better therapies for patients.
Many oncology patients receive marginal benefits from their therapies while often enduring debilitating side effects. Even with the extensive knowledge and technology that has produced today’s targeted therapies, there remains much room for improvement. Over the past years, we developed the Biomea FUSION™ System to take a substantial leap forward in drug development. Most drugs are reversibly binding to their target, requiring constant exposure which can lead to a toxic side effect profile while often only marginally inhibiting the target. We are focused on irreversibly bound drugs, which are commonly ignored due to their design and chemistry complexities.
We believe that irreversibly bound therapies can achieve a more constant inhibition of the targeted pathway with much less drug applied, and a reduced burden on the patient. We strive to create patient-friendly therapies that provide long, durable responses against aggressive tumors.
